The Lancet – Les Tromperies de la Renommée

Dr. Ariel Beresniak, CEO and founder of Data Mining International reviews in this article in Causeur magazine, the highly controversial situation where the internationally reputed scientific journal The Lancet took its distance from the study it had previously published on the dangers of chloroquine.

Please click on the image for access to the full article:

2020-09-02T12:29:30+02:00June 6th, 2020|Categories: Articles|Tags: , , , |

Cost of human life during COVID pandemic

Dr. Ariel Beresniak presents an analysis behind economic decisions being made amidst Covid-19, in this article for Causeur Magazine in May 2020.


Please click on the image for access to the full article:

2020-07-31T18:05:49+02:00May 18th, 2020|Categories: Articles|

Hydroxychloroquine in COVID: What is a “proof” ?

During unsettling Covid-19 times of emergency, Dr. Ariel Beresniak puts science back to its rightful place as a benchmark for decision-making, in this article published in Causeur magazine on 4th May 2020.

Please click on the image for access to the full article:

2020-07-31T18:08:35+02:00May 4th, 2020|Categories: Articles|

Test-and-treat strategy using Urea Breath Tests is cost-effective in managing symptoms and consequences from Helicobacter Pylori infection

Test-and-treat strategy using Urea Breath Tests is proven to be cost-effective in managing symptoms and consequences from Helicobacter pylori infection, thus contributing to preventing peptic ulcer and gastric cancer.

For more information regarding this subject please refer to our Press Release.

2020-07-31T11:49:09+02:00February 4th, 2019|Categories: Articles|

DMI presents the QALYs’ inadequacies during the Ethics Prize Seminar in Stockholm

Dr Ariel Beresniak took part in the Ethics Prize Seminar in Stockholm in October 2016, where he discussed once again how inadequate, inaccurate and unethical the QALY approach is when used for making a decision about new medicines’ access to patients in need. 

This seminar was organised by the Swedish Council of Medical Ethics.

The full seminar broadcast can be viewed here. Dr Ariel Beresniak’s presentation starts at 1:50:13.

More information on the QALYs and DMI’s role in the ECHOUTCOME project: www.echoutcome.eu.

2020-07-31T11:49:09+02:00December 19th, 2016|Categories: Articles|

New publication related to the EHR4CR project on the re-use of the electronic health data

The European research project Electronic Health Records for Clinical Research (EHR4CR) was co-funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the Innovative Medicines Initiative. A new budgetary impact assessment published in the Journal of Health & Medical Informatics reveals that compared to current practices, the EHR4CR platform appears cost-saving for pharmaceutical industry, the primary sponsor of clinical trials.

 

The full article is available here.

More information on the EHR4CR project: www.ehr4cr.eu.

2020-07-31T11:49:09+02:00August 9th, 2016|Categories: Articles|

Public Health promoted by Classical Music – a concert-conference hosted by DMI in the frame of the ASSET project

It is a well-known fact how music positively affects the intellectual development and improves the concentration. This relationship, appreciated by musicians and music fans is gradually gaining more attention also from the scientific research teams around the world. The scientific consortium ASSET, financed by the European Commission, proposes a unique way of integrating classical music in the promotion of public health by organising a piano concert where the classical piano pieces will be accompanied by the presentations of six international scientific experts.

“Concerto for Piano and Sciences” is the first event of this kind […]

2020-07-31T11:49:09+02:00July 13th, 2016|Categories: Articles|

DMI will discuss the QALY approach and its risks during the next HTAi conference in Tokyo, Japan

Data Mining International will be participating in the symposium arranged by Pfizer during the next HTAi conference in Tokyo, in order to present the risks and inadequacies of the QALY approach used for resource allocations by several countries’ national health reimbursement systems. DMI will also discuss the scientifically more valid and robust alternatives to determine the cost-effectiveness of new medicines and technologies that can be confidently used in place of QALYs.

The information about the HTAi, 10-14 May 2016:

http://meeting.htai.org/events/tokyo2016/event-summary-4023afce0ec04ab387500e87f0a6a42d.aspx

Back to News

2020-07-31T11:49:09+02:00May 3rd, 2016|Categories: Articles|